Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 2 (1)
P 4 (2)

Trial Status

Recruiting4
Enrolling By Invitation1
Not Yet Recruiting1
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT06655480Phase 2RecruitingPrimary

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

NCT05115890Not ApplicableRecruitingPrimary

Muscle Blood Flow Regulation in HFpEF

NCT06844032RecruitingPrimary

Predictors of Poor Prognosis in HFpEF

NCT07298993Phase 4Enrolling By Invitation

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07270536Not ApplicableRecruitingPrimary

Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction

NCT07147114Phase 4Not Yet Recruiting

Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)

NCT06916611Active Not RecruitingPrimary

Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes

Showing all 7 trials

Research Network

Activity Timeline